The improvements in hemodynamic parameters, biochemical markers, lipid profile, and glucose regulation, along with the potential role of Nrf2 activation and the reduction of IL-6 and IL-1β, indicate that BCA could be a promising therapeutic candidate for managing diabetic cardiovascular complications. This evidence concerns the gene NFE2L2 and diabetes mellitus.